Skip to main content

Table 2 Association of PON1 Q192R polymorphism with glycemia, insulin secretion, and sensitivity after stratified analysis by statin therapy

From: The gene–treatment interaction of paraoxonase-1 gene polymorphism and statin therapy on insulin secretion in Japanese patients with type 2 diabetes: Fukuoka diabetes registry

  

FPG, mmol/l

HbA1c, % (mmol/mol)

Logarithm of C-peptide

Logarithm of HOMA2-%β

Logarithm of HOMA2-IR

Statin (−)

QQ

7.75 ± 2.02

7.23 ± 0.95 (55.5 ± 10.4)

0.19 ± 0.39

3.69 ± 0.45

0.02 ± 0.43

QR

7.66 ± 2.04

7.28 ± 1.03 (56.1 ± 11.2)

0.16 ± 0.38

3.69 ± 0.48

−0.02 ± 0.41

RR

7.73 ± 2.06

7.35 ± 1.05 (56.8 ± 11.5)

0.19 ± 0.39

3.69 ± 0.50

0.01 ± 0.41

P value

0.82

0.07

0.47

0.8

0.47

Statin (+)

QQ

7.51 ± 1.79

7.34 ± 0.92 (56.7 ± 10.1)#

0.27 ± 0.40#

3.80 ± 0.49#

0.09 ± 0.41

QR

7.53 ± 1.88#

7.43 ± 0.99 (57.7 ± 10.8)

0.22 ± 0.38

3.76 ± 0.47#

0.04 ± 0.40

RR

7.81 ± 1.98

7.56 ± 1.07 (59.1 ± 11.7)

0.19 ± 0.39

3.67 ± 0.48

0.02 ± 0.42

P value

0.0052

0.0022

0.016

0.0001

0.082

P for interactiona

0.059

0.26

0.022

0.0022

0.074

  1. Data are expressed as mean ± SD; P value refers to simple regression analysis
  2. # P < 0.05 vs. RR genotype
  3. aInteraction of statin therapy with PON1 genotype